The case for supporting OSA as a causal factor of MetS is reliant firstly on demonstrating that co-morbid OSA-MetS is highly prevalent and dose-dependent, and that established OSA precedes development of MetS and/or exacerbation of MetS components. Certainly, multiple cross-sectional studies demonstrate high prevalence rates (50-87%) of MetS in OSA clinic populations (Bonsignore et al. 2013 ) and a high prevalence (60%) of at least moderate OSA in patients with MetS (Drager et al. 2010) . Importantly, many studies have established associations independent of obesity (Bonsignore et al. 2013) . Dose-response relationships also exist between OSA severity and worsening metabolic profiles. For example, the Sleep Heart Health Study (SHHS) showed a dose-response relationship between OSA severity determined from the Respiratory Disturbance Index (RDI) and both reduced HDL and increased triglycerides (Newman et al. 2001) . Several clinical studies have also demonstrated dose-response relationships (Bonsignore et al. 2012; Lin et al. 2012) , even in morbidly obese OSA patients (Gasa et al. 2011) . It is important to acknowledge that although these studies show strong cross-sectional associations between OSA and MetS, they do not prove causality. However recent longitudinal data suggest that OSA predicts the development of new onset MetS (Troxel et al. 2010 ) and longitudinal population data implicate OSA (Botros et al. 2009 ) particularly hypoxemic OSA (Appleton et al. 2015) as a factor in the development of diabetes -a downstream consequence of MetS. Collectively, these epidemiological studies show a strong association between OSA and MetS with some longitudinal data also supporting OSA as a causal factor in the development of MetS and diabetes.
OSA treatment evidence
The case for supporting OSA as a cause of MetS also relies on randomised controlled trial evidence showing that OSA treatment with continuous positive airway pressure (CPAP) reduces MetS prevalence, improves MetS components and/or improves insulin sensitivity, the hallmark of MetS.
MetS prevalence
Three studies found no reduction in the proportion of MetS with CPAP (Coughlin et al. 2007; Hoyos et al. 2013; Salord et al. 2016) . However one study included only ß50% of patients with MetS (Hoyos et al. 2013 ). In the other two studies, a majority of patients were so excessively obese (BMI ࣙ 35 kg m −2 ) that any reduction in MetS prevalence would require a dramatic (20-40 cm) reduction in waist circumference with CPAP, which is unlikely given the short (ࣘ 3 month) treatment period (Coughlin et al. 2007; Salord et al. 2016) . Furthermore, in two studies, CPAP compliance was suboptimal (< 4 h) (Coughlin et al. 2007; Hoyos et al. 2013) . This overall predominance of marked obesity in studies, together with relatively poor CPAP compliance and short treatment periods, is likely to explain the lack of reduction in MetS prevalence.
MetS components
Meta-analyses of multiple trials clearly show that treatment of OSA lowers blood pressure (Bratton et al. 2015) . Overall, the effect is mostly modest (ß2-3 mmHg); however, it is greater (ß5 mmHg) in the presence of resistant hypertension (Liu et al. 2016) .
Aside from blood pressure, however, it has been argued that CPAP fails to reduce MetS-associated metabolic components J Physiol 594.17 (Jullian-Desayes et al. 2015) . We argue that this does not constitute proof in and of itself that OSA is an innocent bystander. Instead, we suggest that the lack of favourable cardio-metabolic effects with CPAP relates to confounding factors including the following. (1) No studies have made abnormal levels of MetS components part of their inclusion criteria. Consequently any studies with predominantly normal levels would be unlikely to conclude that CPAP improves cardio-metabolic health. (2) Many analyses of metabolic components were secondary and likely to have lacked statistical power to reliably assess treatment effects. (3) Many intention to treat analyses included patients who were poorly compliant with CPAP. (4) Many studies base findings on relatively short (<3 months) treatment periods when longer term treatment may reveal benefits. (5) Many studies that show no effect of CPAP on insensitive measures of metabolism found benefits with more sensitive measures. Examples of studies examining the MetS components of glucose, central obesity and dyslipidaemia where these confounding factors were evident are discussed below.
Glucose metabolism
Eight randomised trials (Coughlin et al. 2007; West et al. 2007; Comondore et al. 2009; Lam et al. 2010; Hoyos et al. 2012; Sivam et al. 2012; Pamidi et al. 2015; Salord et al. 2016 ) examined the MetS component of fasting glucose. Whilst no trial demonstrated any reduction with CPAP, in half the studies fasting glucose was within normal limits (Coughlin et al. 2007; Comondore et al. 2009; Lam et al. 2010; Hoyos et al. 2012) . Importantly six trials also dynamically assessed glucose metabolism (West et al. 2007; Lam et al. 2010; Hoyos et al. 2012; Weinstock et al. 2012; Pamidi et al. 2015; Salord et al. 2016) and in contrast to fasting glycaemia, three trials found improvements in glucose tolerance or insulin sensitivity. In all trials, CPAP use exceeded 5.4 h (Lam et al. 2010; Pamidi et al. 2015; Salord et al. 2016) . However, in three trials which showed no improvements, CPAP use was lower (West et al. 2007; Hoyos et al. 2012; Weinstock et al. 2012) with two studies having compliances of only 3.6 h (West et al. 2007; Hoyos et al. 2012 ). In one study, patients with severe OSA showed marked improvements in both glucose tolerance and insulin sensitivity that were dose dependent with CPAP compliance (Weinstock et al. 2012) . Overall, this lack of CPAP effect on fasting glucose in many studies may be explained by normal baseline glucose levels. However, in support of OSA as a cause of insulin resistance, improvements in dynamic and more sensitive measures of glucose metabolism do occur with high CPAP compliance, particularly in severe OSA.
Central obesity
Whilst obesity is causally linked to OSA, some studies suggest that OSA may itself be obesogenic. In the SHHS, OSA severity was positively associated with the 5-year increase in BMI after adjustment for known confounders (Brown et al. 2011) . Furthermore, in a weight loss study (Borel et al. 2012 ) men with OSA had smaller reductions in weight, waist circumference and lipids compared to men without OSA. Worsening levels of baseline hypoxia were associated with less visceral abdominal fat (VAF) loss and smaller improvements in glucose tolerance at 1 year. These data support OSA as an important modulator of body weight.
However, without long-term trials involving effective elimination of OSA with high CPAP compliance it is still unclear whether central obesity can be reduced. For example, there are four studies that found no reduction in waist circumference with CPAP (West et al. 2007; Lam et al. 2010; Hoyos et al. 2012; Salord et al. 2016) . In another four trials there was no reduction in VAF with CPAP (Hoyos et al. 2012; Sivam et al. 2012; Weinstock et al. 2012; Kritikou et al. 2013) . However, in three of these four studies, compliance was less than 5 h and treatment duration was only 8 weeks. VAF did decrease in all studies (although not significantly), raising the possibility that positive effects may occur with long-term compliant CPAP use. Of note, two trials found improvements in growth (GH) and insulin sensitising (IGF-1) hormones with CPAP (Munzer et al. 2010; Hoyos et al. 2014) , which are consistent with longer term increases in lean body mass (Munzer et al. 2010; Hoyos et al. 2012) . In this context, the consistently small (ß0.5 kg) increase in body weight that occurs with CPAP shown in a recent meta-analysis of randomized controlled trials (RCTs; Drager et al. 2015) may be entirely attributable to CPAP-associated increases in metabolically healthy muscle mass. However further long-term trials that quantify both fat and lean mass changes with CPAP are still required to clarify the impact of CPAP on body weight.
Finally, although it has been difficult to separate the effects of OSA from those of obesity, a recent RCT (Chirinos et al. 2014) found that weight loss of more than 10 kg when combined with compliant CPAP use reduced blood pressure more than weight loss alone or CPAP therapy alone. Combined therapy was the only approach that improved insulin sensitivity from baseline and also provided the greatest improvement in triglycerides although both measures were not statistically different from weight loss alone. Overall this study suggests that persistent OSA inhibits potential weight loss induced cardio-metabolic improvements.
Dyslipidaemia
No randomised trials have documented reductions in fasting triglycerides with CPAP (Jullian-Desayes et al. 2015) . However, as with glucose, dynamic testing with assessment of disposal of triglycerides after meals has shown improvements with CPAP treatment, consistent with improved food-based fat metabolism (Phillips et al. 2011) . Finally, although no RCTs have documented increased levels of fasting HDL cholesterol with CPAP (Coughlin et al. 2007; Comondore et al. 2009; Phillips et al. 2011; Salord et al. 2016) , all study levels were within normal limits suggesting little room for improvement. Importantly, two recent meta-analyses both suggest a lowering of total cholesterol with one analysis also suggesting lower LDL and higher HDL cholesterol following CPAP treatment (Nadeem et al. 2014; Xu et al. 2014) .
Mechanisms
Several OSA-related mechanisms including oxidative stress, sympathetic activation, hypoxia and sleep fragmentation are proposed mediators of cardio-metabolic dysfunction (Mesarwi et al. 2015) . For example, exposure to acute intermittent hypoxia in healthy humans elevates sympathetic activity and blood pressure and causes insulin resistance. Furthermore, sympathetic inhibition attenuates hypoxia-induced insulin resistance (Mesarwi et al. 2015) . These studies provide clear mechanistic support for OSA as a cause of hypertension and insulin resistance and suggest that the complete reversal of OSA with all-night CPAP will improve both (Pamidi et al. 2015) .
Conclusion
Whilst it is without dispute that obesity is a primary cause of OSA, there are no data to support the hypothesis that MetS or any MetS component causes OSA. In contrast, there are many epidemiological, treatment and mechanistic studies supporting the alternative -that OSA promotes MetS through exacerbation of its key cardio-metabolic components and consequences.
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